Oppenheimer Upgrades Blueprint Medicines (BPMC) to Outperform; 'We Want In on this Launch'
Tweet Send to a Friend
(Updated - October 27, 2023 7:31 AM EDT)
Oppenheimer analyst Matthew Biegler upgraded Blueprint Medicines (NASDAQ: BPMC) from Perform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Matthew Biegler upgraded Blueprint Medicines (NASDAQ: BPMC) from Perform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
